Michael Kremer has been appointed Chief Economist of the World Bank Group (WBG), one of the largest multilateral funders of health systems globally, amid funding cuts and the closure of USAID. He is the first economist to enter the role after having already received a Nobel Prize. More importantly, Kremer brings extensive experience in translating rigorous research into programs that have reached hundreds of millions of people across areas including vaccines, school health, water, and agriculture. His appointment comes at a time when the WBG is changing its outlook, structure, and organization, and his path to success at the World Bank Group might not be straightforward.
His appointment appears closely aligned with World Bank President Ajay Banga’s jobs agenda. The Bank estimates that 1.2 billion young people will reach working age over the coming decade. For global health, the central question is whether health will be recognized as a foundation for productive employment or treated merely as an outcome of economic prosperity. Kremer’s work across sectors suggests that he understands how investments in human capital enable people to participate in the economy. However, whether he can translate that understanding into sustained space for health-systems innovation remains an open question. Early opportunities exist for him through the National Health Compacts, which frame stronger health systems not only as a route to affordable care, but also as a source of jobs and broader economic growth.
The second major push is the Bank’s growing emphasis on mobilizing private capital. In fiscal year 2026, WBG mobilized $112 billion, up from $35 billion in 2022. Across Africa, private capital mobilization rose from approximately $9 billion to $22 billion—an increase of nearly 150 percent. Kremer’s work on advance market commitments for vaccines offers a model for health: by guaranteeing demand for socially valuable products, public finance can influence private investment. The challenge for him will be to ensure that private capital advances equitable health priorities rather than concentrating only on commercially attractive services and markets.
A third issue is the changing nature of the Bank’s research, data, and analytical agenda, with greater concentration under the Chief Economist’s Office. Kremer will lead this agenda amid the broader reorganization, as the institution seeks to strengthen its role as a knowledge bank rather than merely a development financier. Closer alignment with operations can make research more relevant and useful. However, critics of the Knowledge Bank reorganization warn that private-sector and deal-making priorities could shape which questions are investigated and how evidence is interpreted. This matters for health, where politically sensitive evidence on financing, service quality, and inequalities must remain credible and independent. Protecting that independence while responding to institutional priorities will be a difficult path for Kremer to navigate.
Kremer’s appointment could prove to be a masterstroke. His success, however, will depend on whether he can connect evidence, scale, jobs, and private capital without allowing health equity to become secondary concern.